Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

ABSTRACT Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of
acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Hayes' Principles and Methods of Toxicology has long been established as a reliable and
informative reference for the concepts, methodologies, and assessments integral to …

Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …

Cytochrome P450 enzymes that metabolize estrogens are expressed in the mammary
gland, uterus, brain and other target tissues for estrogen action, and this results in the …

The field of cytochrome P450 pharmacogenetics has progressed rapidly during the past 25
years. All the major human drug-metabolizing P450 enzymes have been identified and …

This document was developed by the Pharmacogenomics (PGx) Working Group of the
Association for Molecular Pathology Clinical Practice Committee, whose aim is to …